Press Room - Sanofi US News
WEB1 day ago · SARCLISA (isatuximab-irfc) is a monoclonal antibody that binds to a specific epitope on the CD38 receptor on MM cells, inducing distinct antitumor activity. It is designed to work through multiple mechanisms of action including programmed tumor cell death (apoptosis) and immunomodulatory activity.
ASCO: Sarclisa is first anti-CD38 to significantly improve ... - Sanofi
WEBJun 3, 2024 · If approved, Sarclisa would be the first anti-CD38 therapy in combination with standard-of-care VRd in newly diagnosed patients not eligible for transplant, which would be the third indication for Sarclisa in multiple myeloma.
Press Release: Sarclisa approved in the US as the first anti-CD38 ...
WEB17 hours ago · In the IMROZ study, Sarclisa-VRd followed by Sarclisa-Rd met the primary endpoint of PFS, significantly reducing the risk of recurrence or death by 40%, compared to VRd followed by Rd, in patients ...
FDA Approves Sarclisa In Newly Diagnosed Transplant-Ineligible …
WEB19 hours ago · Sarclisa was approved by the FDA in 2020 in combination with pomalidomide and dexamethasone for adults with multiple myeloma who received at least two prior therapies including lenalidomide and a proteasome inhibitor. In 2021, it was approved by the agency in combination with Kyprolis (carfilzomib) and dexamethasone to treat adults with ...
Sanofi moves on J&J in first-line myeloma with FDA nod
WEB1 day ago · ASCO: With first-in-class win, Sanofi's Sarclisa looks to step out of J&J's multiple myeloma shadow. Challenging Darzalex won’t be easy. Worldwide sales of the J&J med jumped 22% and reached $9. ...
Press Room - Sanofi US News
WEBAug 8, 2024 · Sarclisa induction treatment demonstrated significantly improved progression-free survival in patients with newly diagnosed multiple myeloma eligible for transplant.
FDA Approves Isatuximab With VRd as First-Line Option for …
WEB18 hours ago · The FDA approved isatuximab (Sarclisa; Sanofi-Aventis) with bortezomib, lenalidomide, and dexamethasone (VRd) for adults who cannot receive autologous stem cell transplant to treat their newly ...
FDA Approves New Therapy for Patients with Previously Treated …
WEBToday, the U.S. Food and Drug Administration approved Sarclisa (isatuximab-irfc), in combination with pomalidomide and dexamethasone, for the treatment of adult patients with multiple myeloma...
Sarclisa® (isatuximab) Phase 3 trial met primary endpoint of
WEBDec 7, 2006 · The Phase 3 IMROZ trial evaluating the investigational use of Sarclisa® (isatuximab) in combination with standard-of-care bortezomib, lenalidomide and dexamethasone (VRd) met its primary endpoint at a planned interim analysis for efficacy.
Sanofi Says FDA Approves Sarclisa for Treatment of Blood Cancer ...
WEB1 day ago · The French pharmaceutical company said Sarclisa was approved in combination with bortezomib, lenalidomide and dexamethasone. Multiple myeloma is a blood cancer that develops in plasma cells. The ...
- Some results have been removed